Age-related differences in management of heart disease: A study of cardiac medication use in an older cohort

Journal of the American Geriatrics Society

Volumn 47, Issue 2, 1999, Pages 145-150

  Ganz, David A ^a,e   Lamas, Gervasio A ^b   Orav, E John ^a,d   Goldman, Lee ^c   Gutierrez, Peter R ^e   Mangione, Carol M ^e,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age; Cardiovascular disease treatment; Variation in care

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; GERIATRIC CARE; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE;

EID: 0032932791     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1999.tb04571.x     Document Type: Article

References (28)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
2. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
5. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
7. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982;247:1707-1714.
8. Petersen P, Godtfredsen J, Boysen G et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989;1:175-179.
9. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
10. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: Final results. Circulation 1991;84:527-539.
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
12. Montague TJ, Wong RY, Burton JR et al. Changes in acute myocardial infarction risk and patterns of practice for patients older and younger than 70 years, 1987-90. Can J Cardiol 1992;8:596-600.
13. Gurwitz JH, Goldberg RJ, Chen Z et al. β-blocker therapy in acute myocardial infarction: Evidence for underutilization in the elderly. Am J Med 1992; 93:605-610.
14. Krumholz HM, Radford MJ, Ellerbeck EF et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries: Patterns of use and outcomes. Circulation 1995;92:2841-2847.
15. Krumholz HM, Radford MJ, Ellerbeck EF et al. Aspirin for secondary prevention after acute myoairdial infarction in the elderly: Prescribed use and outcomes. Ann Intern Med 1996;124:292-298.
16. McLaughlin TJ, Soumerai SB, Willison DJ et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction. Arch Intern Med 1996;156:799-805.
17. Soumerai SB, McLaughlin TJ, Spiegelman D et al. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-121.
18. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. BMJ 1993;307:1045.
19. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-2541.
20. O'Connell JE, Gray CS. Atrial Fibrillation and stroke prevention in the community. Age Ageing 1996;25:307-309.
21. Lamas GA, Orav EJ, Stambler BS et al. Quality of life and clinical events in elderly patients randomized to ventricular versus dual chamber pacing. N Engl J Med 1998;338:1097-1104.
22. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
23. Krumholz HM, Vaccarino V, Ellerbeck EF et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in person ≥ 65 years of age. Am J Cardiol 1997;79:581-586.
24. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-1953.
25. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997;157: 441-445.
26. Lamas GA, Pfeffer MA, Hamm P et al. for the SAVE Investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med 1992;327:241-247.
27. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992;268:1417-1422.
28. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new Specific Activity Scale. Circulation 1981;64:1227-1234.